Recursion Pharmaceuticals, Inc. Financials
This page shows Recursion Pharmaceuticals, Inc. (RXRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Recursion Pharmaceuticals, Inc. has an operating margin of -867.9%, meaning the company retains $-868 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -814.1% the prior year.
Recursion Pharmaceuticals, Inc.'s revenue surged 26.9% year-over-year to $74.7M, reflecting rapid business expansion. This strong growth earns a score of 78/100.
Recursion Pharmaceuticals, Inc. carries a low D/E ratio of 0.01, meaning only $0.01 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 5.50, Recursion Pharmaceuticals, Inc. holds $5.50 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Recursion Pharmaceuticals, Inc. generated -$371.8M in operating cash flow, capex of $6.5M consumed most of it, leaving -$378.3M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Recursion Pharmaceuticals, Inc. generates a -57.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -44.8% the prior year.
Recursion Pharmaceuticals, Inc. passes 4 of 9 financial strength tests. 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Recursion Pharmaceuticals, Inc. generates $0.58 in operating cash flow (-$371.8M OCF vs -$644.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Recursion Pharmaceuticals, Inc. earns $-358.1 in operating income for every $1 of interest expense (-$648.1M vs $1.8M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Recursion Pharmaceuticals, Inc. generated $74.7M in revenue in fiscal year 2025. This represents an increase of 26.9% from the prior year.
Recursion Pharmaceuticals, Inc.'s EBITDA was -$564.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 27.6% from the prior year.
Recursion Pharmaceuticals, Inc. reported -$644.8M in net income in fiscal year 2025. This represents a decrease of 39.1% from the prior year.
Recursion Pharmaceuticals, Inc. earned $-1.44 per diluted share (EPS) in fiscal year 2025. This represents an increase of 14.8% from the prior year.
Cash & Balance Sheet
Recursion Pharmaceuticals, Inc. generated -$378.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 1.5% from the prior year.
Recursion Pharmaceuticals, Inc. held $743.3M in cash against $9.6M in long-term debt as of fiscal year 2025.
Recursion Pharmaceuticals, Inc. had 528M shares outstanding in fiscal year 2025. This represents an increase of 33.1% from the prior year.
Margins & Returns
Recursion Pharmaceuticals, Inc.'s gross margin was 5.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 18.1 percentage points from the prior year.
Recursion Pharmaceuticals, Inc.'s operating margin was -867.9% in fiscal year 2025, reflecting core business profitability. This is down 53.8 percentage points from the prior year.
Recursion Pharmaceuticals, Inc.'s net profit margin was -863.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 75.3 percentage points from the prior year.
Recursion Pharmaceuticals, Inc.'s ROE was -57.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 12.2 percentage points from the prior year.
Capital Allocation
Recursion Pharmaceuticals, Inc. invested $475.3M in research and development in fiscal year 2025. This represents an increase of 51.2% from the prior year.
Recursion Pharmaceuticals, Inc. invested $6.5M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 52.8% from the prior year.
RXRX Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $35.5M+586.7% | $5.2M-73.1% | $19.2M+30.4% | $14.7M+224.4% | $4.5M-82.6% | $26.1M+80.9% | $14.4M+4.5% | $13.8M |
| Cost of Revenue | $14.3M-2.8% | $14.7M-27.2% | $20.2M-7.6% | $21.8M+70.6% | $12.8M+5.9% | $12.1M+31.3% | $9.2M-17.6% | $11.2M |
| Gross Profit | $21.3M+323.5% | -$9.5M-914.1% | -$938K+86.8% | -$7.1M+14.1% | -$8.2M-158.9% | $14.0M+168.4% | $5.2M+98.6% | $2.6M |
| R&D Expenses | $95.9M-20.8% | $121.1M-5.9% | $128.6M-0.8% | $129.6M+31.8% | $98.3M+31.8% | $74.6M+0.9% | $73.9M+9.4% | $67.6M |
| SG&A Expenses | $33.7M-19.1% | $41.6M-10.8% | $46.7M-14.6% | $54.6M-29.2% | $77.2M+104.4% | $37.8M+18.6% | $31.8M+1.4% | $31.4M |
| Operating Income | -$108.3M+37.1% | -$172.2M+2.3% | -$176.2M+7.9% | -$191.4M-4.1% | -$183.8M-86.8% | -$98.4M+2.2% | -$100.5M-4.4% | -$96.3M |
| Interest Expense | -$11K-101.3% | $833K+73.5% | $480K-5.5% | $508K-16.0% | $605K+9.4% | $553K+40.4% | $394K+1870.0% | $20K |
| Income Tax | $19K+533.3% | $3K | $0+100.0% | -$158K-2075.0% | $8K-95.2% | $167K+131.9% | -$523K+32.9% | -$779K |
| Net Income | -$108.1M+33.4% | -$162.3M+5.6% | -$171.9M+15.1% | -$202.5M-13.2% | -$178.9M-86.7% | -$95.8M+1.7% | -$97.5M-6.7% | -$91.4M |
| EPS (Diluted) | N/A | $-0.36+12.2% | $-0.41+18.0% | $-0.50 | N/A | $-0.34+15.0% | $-0.40-2.6% | $-0.39 |
RXRX Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.5B+5.3% | $1.4B+7.5% | $1.3B-0.2% | $1.3B-9.9% | $1.4B+99.4% | $726.5M-6.4% | $775.9M+39.1% | $557.8M |
| Current Assets | $812.8M+13.8% | $714.1M+21.6% | $587.2M+0.5% | $584.1M-18.2% | $714.3M+50.6% | $474.2M-9.2% | $522.4M+52.0% | $343.6M |
| Cash & Equivalents | $743.3M+12.6% | $659.8M+25.7% | $525.1M+4.9% | $500.5M-15.8% | $594.4M+39.0% | $427.6M-9.8% | $474.3M+60.1% | $296.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $162.2M+0.1% | $162.0M-1.4% | $164.3M+3.9% | $158.1M+6.2% | $148.9M+186.0% | $52.1M0.0% | $52.1M0.0% | $52.1M |
| Total Liabilities | $343.3M-2.6% | $352.6M-8.0% | $383.2M+3.2% | $371.3M-10.3% | $413.8M+104.9% | $201.9M+5.5% | $191.4M+22.2% | $156.7M |
| Current Liabilities | $147.7M-4.8% | $155.1M-5.4% | $164.0M+15.5% | $142.0M-24.3% | $187.5M+72.2% | $108.9M+26.5% | $86.1M+16.5% | $73.9M |
| Long-Term Debt | $9.6M-19.6% | $11.9M-16.2% | $14.2M-13.7% | $16.4M-13.5% | $19.0M-7.3% | $20.5M-10.5% | $22.9M | N/A |
| Total Equity | $1.1B+8.0% | $1.0B+13.9% | $919.1M-1.6% | $933.9M-9.7% | $1.0B+97.3% | $524.6M-10.2% | $584.4M+45.7% | $401.2M |
| Retained Earnings | -$2.1B-5.5% | -$2.0B-9.0% | -$1.8B-10.5% | -$1.6B-14.1% | -$1.4B-14.3% | -$1.3B-8.3% | -$1.2B-9.2% | -$1.1B |
RXRX Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$46.1M+60.7% | -$117.4M-53.6% | -$76.4M+42.1% | -$132.0M-14.3% | -$115.4M-94.9% | -$59.2M+28.0% | -$82.2M+19.6% | -$102.3M |
| Capital Expenditures | $1.2M+411.9% | $243K-92.3% | $3.1M+71.9% | $1.8M+41.1% | $1.3M-71.5% | $4.6M+286.0% | $1.2M-82.2% | $6.7M |
| Free Cash Flow | -$47.3M+59.8% | -$117.6M-47.8% | -$79.6M+40.5% | -$133.8M-14.6% | -$116.7M-83.0% | -$63.8M+23.5% | -$83.4M+23.5% | -$109.0M |
| Investing Cash Flow | -$1.2M+51.2% | -$2.5M+56.1% | -$5.8M+20.1% | -$7.3M-102.6% | $275.5M+6138.1% | -$4.6M-9.1% | -$4.2M+37.1% | -$6.7M |
| Financing Cash Flow | $132.0M-47.5% | $251.3M+157.4% | $97.7M+141.0% | $40.5M+280.9% | $10.6M-35.4% | $16.5M-93.7% | $263.1M+1793.4% | $13.9M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
RXRX Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.8%+243.6pp | -183.8%-178.9pp | -4.9%+43.2pp | -48.0%+133.4pp | -181.4%-235.1pp | 53.7%+17.5pp | 36.2%+17.1pp | 19.1% |
| Operating Margin | -304.8%+3022.7pp | -3327.6%-2410.8pp | -916.8%+381.1pp | -1297.9%+2744.5pp | -4042.4%-3665.3pp | -377.1%+320.3pp | -697.4%+1.0pp | -698.4% |
| Net Margin | -304.2%+2831.1pp | -3135.3%-2241.1pp | -894.2%+479.0pp | -1373.3%+2562.2pp | -3935.5%-3568.0pp | -367.5%+309.1pp | -676.6%-14.1pp | -662.4% |
| Return on Equity | -9.6%+5.9pp | -15.5%+3.2pp | -18.7%+3.0pp | -21.7%-4.4pp | -17.3%+1.0pp | -18.3%-1.6pp | -16.7%+6.1pp | -22.8% |
| Return on Assets | -7.3%+4.3pp | -11.6%+1.6pp | -13.2%+2.3pp | -15.5%-3.2pp | -12.3%+0.8pp | -13.2%-0.6pp | -12.6%+3.8pp | -16.4% |
| Current Ratio | 5.50+0.9 | 4.60+1.0 | 3.58-0.5 | 4.11+0.3 | 3.81-0.5 | 4.35-1.7 | 6.07+1.4 | 4.65 |
| Debt-to-Equity | 0.010.0 | 0.010.0 | 0.020.0 | 0.020.0 | 0.02-0.0 | 0.040.0 | 0.04-0.4 | 0.39 |
| FCF Margin | -133.1%+2139.4pp | -2272.5%-1858.6pp | -413.9%+493.4pp | -907.3%+1660.4pp | -2567.7%-2323.2pp | -244.6%+333.9pp | -578.5%+211.4pp | -789.9% |
Similar Companies
Frequently Asked Questions
What is Recursion Pharmaceuticals, Inc.'s annual revenue?
Recursion Pharmaceuticals, Inc. (RXRX) reported $74.7M in total revenue for fiscal year 2025. This represents a 26.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Recursion Pharmaceuticals, Inc.'s revenue growing?
Recursion Pharmaceuticals, Inc. (RXRX) revenue grew by 26.9% year-over-year, from $58.8M to $74.7M in fiscal year 2025.
Is Recursion Pharmaceuticals, Inc. profitable?
No, Recursion Pharmaceuticals, Inc. (RXRX) reported a net income of -$644.8M in fiscal year 2025, with a net profit margin of -863.4%.
What is Recursion Pharmaceuticals, Inc.'s EBITDA?
Recursion Pharmaceuticals, Inc. (RXRX) had EBITDA of -$564.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Recursion Pharmaceuticals, Inc. have?
As of fiscal year 2025, Recursion Pharmaceuticals, Inc. (RXRX) had $743.3M in cash and equivalents against $9.6M in long-term debt.
What is Recursion Pharmaceuticals, Inc.'s gross margin?
Recursion Pharmaceuticals, Inc. (RXRX) had a gross margin of 5.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Recursion Pharmaceuticals, Inc.'s operating margin?
Recursion Pharmaceuticals, Inc. (RXRX) had an operating margin of -867.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Recursion Pharmaceuticals, Inc.'s net profit margin?
Recursion Pharmaceuticals, Inc. (RXRX) had a net profit margin of -863.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Recursion Pharmaceuticals, Inc.'s return on equity (ROE)?
Recursion Pharmaceuticals, Inc. (RXRX) has a return on equity of -57.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Recursion Pharmaceuticals, Inc.'s free cash flow?
Recursion Pharmaceuticals, Inc. (RXRX) generated -$378.3M in free cash flow during fiscal year 2025. This represents a -1.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Recursion Pharmaceuticals, Inc.'s operating cash flow?
Recursion Pharmaceuticals, Inc. (RXRX) generated -$371.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Recursion Pharmaceuticals, Inc.'s total assets?
Recursion Pharmaceuticals, Inc. (RXRX) had $1.5B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Recursion Pharmaceuticals, Inc.'s capital expenditures?
Recursion Pharmaceuticals, Inc. (RXRX) invested $6.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Recursion Pharmaceuticals, Inc. spend on research and development?
Recursion Pharmaceuticals, Inc. (RXRX) invested $475.3M in research and development during fiscal year 2025.
What is Recursion Pharmaceuticals, Inc.'s current ratio?
Recursion Pharmaceuticals, Inc. (RXRX) had a current ratio of 5.50 as of fiscal year 2025, which is generally considered healthy.
What is Recursion Pharmaceuticals, Inc.'s debt-to-equity ratio?
Recursion Pharmaceuticals, Inc. (RXRX) had a debt-to-equity ratio of 0.01 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Recursion Pharmaceuticals, Inc.'s return on assets (ROA)?
Recursion Pharmaceuticals, Inc. (RXRX) had a return on assets of -43.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Recursion Pharmaceuticals, Inc.'s cash runway?
Based on fiscal year 2025 data, Recursion Pharmaceuticals, Inc. (RXRX) had $743.3M in cash against an annual operating cash burn of $371.8M. This gives an estimated cash runway of approximately 24 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Recursion Pharmaceuticals, Inc.'s Piotroski F-Score?
Recursion Pharmaceuticals, Inc. (RXRX) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Recursion Pharmaceuticals, Inc.'s earnings high quality?
Recursion Pharmaceuticals, Inc. (RXRX) has an earnings quality ratio of 0.58x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Recursion Pharmaceuticals, Inc. cover its interest payments?
Recursion Pharmaceuticals, Inc. (RXRX) has an interest coverage ratio of -358.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. (RXRX) scores 46 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.